ARGENX SE (ARGX) is a reputable, global biopharmaceutical company focused on developing a world-class portfolio of differentiated antibody therapeutics for the treatment of severe autoimmune diseases and cancer. The company, incorporated in 2008, is located in the Netherlands and operates additional offices in Belgium and the United States.
One of the company's well-renowned products, Efgartigimod, is an innovative drug in the clinic for the treatment of neuromuscular and haematological indications. The company prides itself in its industry-leading SIMPLE Antibody™ platform, which descends from the powerful llama immune system. Using this platform, ARGENX SE aims to move its discovery programs into the clinic, such as ARGX-115 which is a first-in-class immunotherapy targeting GARP, a novel immune checkpoint.
ARGENX SE adopts a collaborative model in its operations, partnering with renowned global industry players in a bid to enhance its innovative efforts. To date, the company has struck partnerships with companies like Johnson and Johnson, Burrill, and AbbVie, through which they have managed to make significant advancements in their research and development efforts.
The company is powered by a team of biotech enthusiasts, who bring their worldwide experience and passion together to create breakthrough drugs that transform the lives of patients. With a market capitalization of over €8 Billion, it is evident that ARGENX SE’s operations are well recognized in the biotechnology market. The company's shares are listed in the Nasdaq Global Select Market and the Euronext Brussels stock exchange, providing investors with liquid access to participate in their revolutionary research activities.
As the company advances, it continues to live by its motto “crisp thinking, clear results” as it seeks innovative solutions to curb severe autoimmune diseases and cancers. The combination of a distinctive research platform, a pipeline of promising novel therapies, and strategic partnerships place ARGENX SE at the forefront of antibody biotechnology, assuring its global prominence and profitability in the future.